Pharmacotherapy of patients with schizophrenia and substance abuse

Bibliography

• Wobrock T, Pajonk FG, D'Amelio R, Falkai P. Schizophrenia and addiction. PsychoNeuro 2005;31(9):433-40
   Google Scholar
• Cantor-Graae E, Nordstrom LG, McNeil TF. Substance abuse in schizophrenia: a review of the literature and a study of correlates in Sweden. Schizophr Res 2001;48(1):69-82
   PubMed Web of Science ®Google Scholar
• Mueser KT, Yarnold PR, Levinson DF, et al. Prevalence of substance abuse in schizophrenia: demographic and clinical correlates. Schizophr Bull 1990;16(1):31-56
   PubMed Web of Science ®Google Scholar
• Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990;264(19):2511-8
   PubMed Web of Science ®Google Scholar
• Cohen LJ, Test MA, Brown RL. Suicide and schizophrenia: data from a prospective community treatment study. Am J Psychiatry 1990;147(5):602-7
   PubMed Web of Science ®Google Scholar
• Haywood TW, Kravitz HM, Grossman LS, et al. Predicting the “revolving door” phenomenon among patients with schizophrenic, schizoaffective, and affective disorders. Am J Psychiatry 1995;152(6):856-61
   PubMed Web of Science ®Google Scholar
• Kovasznay B, Fleischer J, Tanenberg-Karant M, et al. Substance use disorder and the early course of illness in schizophrenia and affective psychosis. Schizophr Bull 1997;23(2):195-201
   PubMed Web of Science ®Google Scholar
• Linszen DH, Dingemans PM, Lenior ME. Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry 1994;51(4):273-9
   PubMed Web of Science ®Google Scholar
• Rasanen P, Tiihonen J, Isohanni M, et al. Schizophrenia, alcohol abuse, and violent behavior: a 26-year followup study of an unselected birth cohort. Schizophr Bull 1998;24(3):437-41
   PubMed Web of Science ®Google Scholar
• Seibyl JP, Satel SL, Anthony D, et al. Effects of cocaine on hospital course in schizophrenia. J Nerv Ment Dis 1993;181(1):31-7
   PubMed Web of Science ®Google Scholar
• Soyka M, Albus M, Kathmann N, et al. Prevalence of alcohol and drug abuse in schizophrenic inpatients. Eur Arch Psychiatry Clin Neurosci 1993;242(6):362-72
   PubMed Web of Science ®Google Scholar
• Swofford CD, Kasckow JW, Scheller-Gilkey G, Inderbitzin LB. Substance use: a powerful predictor of relapse in schizophrenia. Schizophr Res 1996;20(1-2):145-51
   PubMed Web of Science ®Google Scholar
• Mueser KT, Drake RE, Wallach MA. Dual diagnosis: a review of etiological theories. Addict Behav 1998;23(6):717-34
   PubMed Web of Science ®Google Scholar
• Falkai P, Wobrock T, Lieberman J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia. World J Biol Psychiatry 2005;6(3):132-91
   PubMed Web of Science ®Google Scholar
• Soyka M, Kranzler HR, Berglund M, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Substance Use and Related Disorders, Part 1: Alcoholism. World J Biol Psychiatry 2008;9(1):6-23
   PubMed Web of Science ®Google Scholar
• Drake RE, Mueser KT. Psychosocial approaches to dual diagnosis. Schizophr Bull 2000;26(1):105-18
   PubMed Web of Science ®Google Scholar
• Wobrock T, Falkai P, Pajonk FG. Acute treatment of schizophrenia. Fortschr Neurol Psychiatr 2004;72(12):705-23
   PubMed Web of Science ®Google Scholar
• Green AI. Pharmacotherapy for schizophrenia and co-occurring substance use disorders. Neurotox Res 2007;11(1):33-40
   PubMed Web of Science ®Google Scholar
• Wobrock T, Soyka M. Pharmacotherapy of schizophrenia with comorbid substance use disorder–reviewing the evidence and clinical recommendations. Prog Neuropsychopharmacol Biol Psychiatry 2008;32(6):1375-85
   PubMed Web of Science ®Google Scholar
• Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976;192(4238):481-3
   PubMed Web of Science ®Google Scholar
• Fleischhacker WW. Second generation antipsychotics. Psychopharmacology (Berl) 2002;162(1):90-1
   PubMed Web of Science ®Google Scholar
• Moller HJ. Definition, psychopharmacological basis and clinical evaluation of novel/atypical neuroleptics: methodological issues and clinical consequences. World J Biol Psychiatry 2000;1(2):75-91
   PubMedGoogle Scholar
• Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353(12):1209-23
   PubMed Web of Science ®Google Scholar
• Soyka M. Dual diagnosis in patients with schizophrenia. Issues in pharmacological treatment. CNS Drugs 1996;5:414-25
   Web of Science ®Google Scholar
• Wilkins JN. Pharmacotherapy of schizophrenia patients with comorbid substance abuse. Schizophr Bull 1997;23(2):215-28
   PubMed Web of Science ®Google Scholar
• Bowers MB Jr, Mazure CM, Nelson JC, Jatlow PI. Psychotogenic drug use and neuroleptic response. Schizophr Bull 1990;16(1):81-5
   PubMed Web of Science ®Google Scholar
• Scheller-Gilkey G, Woolwine BJ, Cooper I, et al. Relationship of clinical symptoms and substance use in schizophrenia patients on conventional versus atypical antipsychotics. Am J Drug Alcohol Abuse 2003;29(3):553-66
   PubMed Web of Science ®Google Scholar
• Stuyt EB, Sajbel TA, Allen MH. Differing effects of antipsychotic medications on substance abuse treatment patients with co-occurring psychotic and substance abuse disorders. Am J Addict 2006;15(2):166-73
   PubMed Web of Science ®Google Scholar
• Petrakis IL, Leslie D, Finney JW, Rosenheck R. Atypical antipsychotic medication and substance use-related outcomes in the treatment of schizophrenia. Am J Addict 2006;15(1):44-9
   PubMed Web of Science ®Google Scholar
• Swanson J, Van Dorn RA, Swartz MS. Effectiveness of atypical antipsychotics for substance use in schizophrenia patients. Schizophr Res 2007;94(1-3):114-8
   PubMed Web of Science ®Google Scholar
• Brunette MF, Drake RE, Xie H, et al. Clozapine use and relapses of substance use disorder among patients with co-occurring schizophrenia and substance use disorders. Schizophr Bull 2006;32(4):637-43
   PubMed Web of Science ®Google Scholar
• Buckley P, Thompson P, Way L, Meltzer HY. Substance abuse among patients with treatment-resistant schizophrenia: characteristics and implications for clozapine therapy. Am J Psychiatry 1994;151(3):385-9
   PubMed Web of Science ®Google Scholar
• Buckley P, Thompson PA, Way L, Meltzer HY. Substance abuse and clozapine treatment. J Clin Psychiatry 1994;55(Suppl B):114-6
   PubMedGoogle Scholar
• Drake RE, Xie H, McHugo GJ, Green AI. The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophr Bull 2000;26(2):441-9
   PubMed Web of Science ®Google Scholar
• Kelly DL, Gale EA, Conley RR. Clozapine treatment in patients with prior substance abuse. Can J Psychiatry 2003;48(2):111-4
   PubMed Web of Science ®Google Scholar
• Lee ML, Dickson RA, Campbell M, et al. Clozapine and substance abuse in patients with schizophrenia. Can J Psychiatry 1998;43(8):855-6
   PubMed Web of Science ®Google Scholar
• Marcus P, Snyder R. Reduction of comorbid substance abuse with clozapine. Am J Psychiatry 1995;152(6):959
   PubMed Web of Science ®Google Scholar
• Zimmet SV, Strous RD, Burgess ES, et al. Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: a retrospective survey. J Clin Psychopharmacol 2000;20(1):94-8
   PubMed Web of Science ®Google Scholar
• Berk M, Brook S, Trandafir AI. A comparison of olanzapine with haloperidol in cannabis-induced psychotic disorder: a double-blind randomized controlled trial. Int Clin Psychopharmacol 1999;14(3):177-80
   PubMed Web of Science ®Google Scholar
• Sayers SL, Campbell EC, Kondrich J, et al. Cocaine abuse in schizophrenic patients treated with olanzapine versus haloperidol. J Nerv Ment Dis 2005;193(6):379-86
   PubMed Web of Science ®Google Scholar
• Smelson DA, Ziedonis D, Williams J, et al. The efficacy of olanzapine for decreasing cue-elicited craving in individuals with schizophrenia and cocaine dependence: a preliminary report. J Clin Psychopharmacol 2006;26(1):9-12
   PubMed Web of Science ®Google Scholar
• Akerele E, Levin FR. Comparison of olanzapine to risperidone in substance-abusing individuals with schizophrenia. Am J Addict 2007;16(4):260-8
   PubMed Web of Science ®Google Scholar
• Littrell KH, Petty RG, Hilligoss NM, et al. Olanzapine treatment for patients with schizophrenia and substance abuse. J Subst Abuse Treat 2001;21(4):217-21
   PubMed Web of Science ®Google Scholar
• Noordsy DL, O'keefe C. Effectiveness of combining atypical antipsychotics and psychosocial rehabilitation in a community mental health center setting. J Clin Psychiatry 1999;60(Suppl 19):47-51; discussion 2-3
   PubMed Web of Science ®Google Scholar
• Noordsy DL, O'Keefe C, Mueser KT, Xie H. Six-month outcomes for patients who switched to olanzapine treatment. Psychiatr Serv 2001;52(4):501-7
   PubMed Web of Science ®Google Scholar
• Gerra G, Di Petta G, D'Amore A, et al. Combination of olanzapine with opioid-agonists in the treatment of heroin-addicted patients affected by comorbid schizophrenia spectrum disorders. Clin Neuropharmacol 2007;30(3):127-35
   PubMed Web of Science ®Google Scholar
• Tsuang J, Marder SR, Han A, Hsieh W. Olanzapine treatment for patients with schizophrenia and cocaine abuse. J Clin Psychiatry 2002;63(12):1180-1
   PubMed Web of Science ®Google Scholar
• Green AI, Tohen MF, Hamer RM, et al. First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophr Res 2004;66(2-3):125-35
   PubMed Web of Science ®Google Scholar
• Conley RR, Kelly DL, Gale EA. Olanzapine response in treatment-refractory schizophrenic patients with a history of substance abuse. Schizophr Res 1998;33(1-2):95-101
   PubMed Web of Science ®Google Scholar
• Brown ES, Nejtek VA, Perantie DC, et al. Cocaine and amphetamine use in patients with psychiatric illness: a randomized trial of typical antipsychotic continuation or discontinuation. J Clin Psychopharmacol 2003;23(4):384-8
   PubMed Web of Science ®Google Scholar
• Potvin S, Stip E, Lipp O, et al. Quetiapine in patients with comorbid schizophrenia-spectrum and substance use disorders: an open-label trial. Curr Med Res Opin 2006;22(7):1277-85
   PubMed Web of Science ®Google Scholar
• Potvin S, Stip E, Roy JY. The effect of quetiapine on cannabis use in 8 psychosis patients with drug dependency. Can J Psychiatry 2004;49(10):711
   PubMed Web of Science ®Google Scholar
• Weisman RL. Quetiapine in the successful treatment of schizophrenia with comorbid alcohol and drug dependence: a case report. Int J Psychiatry Med 2003;33(1):85-9
   PubMed Web of Science ®Google Scholar
• Berk M, Brook S, Nur F. Risperidone compared to haloperidol in cannabis-induced psychotic disorder: a double-blind randomized controlled trial. Int J Psych Clin Pract 2000;4:139
   PubMed Web of Science ®Google Scholar
• Smelson DA, Losonczy MF, Davis CW, et al. Risperidone decreases craving and relapses in individuals with schizophrenia and cocaine dependence. Can J Psychiatry 2002;47(7):671-5
   PubMed Web of Science ®Google Scholar
• Albanese MJ, Khantzian EJ, Murphy SL, Green AI. Decreased substance use in chronically psychotic patients treated with clozapine. Am J Psychiatry 1994;151(5):780-1
   PubMed Web of Science ®Google Scholar
• Gupta N, Basu D. Does risperidone reduce concomitant substance abuse in cases of schizophrenia? Can J Psychiatry 2001;46(9):862-3
   PubMed Web of Science ®Google Scholar
• Tsuang JW, Eckman T, Marder S, Tucker D. Can risperidone reduce cocaine use in substance abusing schizophrenic patients? J Clin Psychopharmacol 2002;22(6):629-30
   PubMed Web of Science ®Google Scholar
• Green AI, Burgess ES, Dawson R, et al. Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone. Schizophr Res 2003;60(1):81-5
   PubMed Web of Science ®Google Scholar
• Kim JH, Kim D, Marder SR. Time to rehospitalization of clozapine versus risperidone in the naturalistic treatment of comorbid alcohol use disorder and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2008;32(4):984-8
   PubMed Web of Science ®Google Scholar
• Beresford TP, Clapp L, Martin B, et al. Aripiprazole in schizophrenia with cocaine dependence: a pilot study. J Clin Psychopharmacol 2005;25(4):363-6
   PubMed Web of Science ®Google Scholar
• Desseilles M, Mathot F. Aripiprazole diminishes cannabis use in schizophrenia. J Neuropsychiatry Clin Neurosci 2008 (Winter);20(1):117-8
   PubMed Web of Science ®Google Scholar
• Dervaux A, Cazali J. Clozapine and amisulpride in refractory schizophrenia and alcohol dependence. J Clin Psychopharmacol 2007;27(5):514-6
   PubMed Web of Science ®Google Scholar
• Swartz MS, Wagner HR, Swanson JW, et al. The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study. Schizophr Res 2008;100(1-3):39-52
   PubMed Web of Science ®Google Scholar
• Soni SD, Brownlee M. Alcohol abuse in chronic schizophrenics: implications for management in the community. Acta Psychiatr Scand 1991;84(3):272-6
   PubMed Web of Science ®Google Scholar
• Levin FR, Evans SM, Coomaraswammy S, et al. Flupenthixol treatment for cocaine abusers with schizophrenia: a pilot study. Am J Drug Alcohol Abuse 1998;24(3):343-60
   PubMed Web of Science ®Google Scholar
• Schilkrut R, Cabrera J, Morales E, Herrera L. Neuroleptics in the treatment of drug dependence in schizophrenics. A study with flupenthixol decanoate. Psychopharmacol 1998;96(Suppl):342
   Google Scholar
• Soyka M, Sand P. Successful treatment with flupenthixol decanoate of a patient with both schizophrenia and alcoholism. Pharmacopsychiatry 1995;28(2):64-5
   PubMed Web of Science ®Google Scholar
• Soyka M, Aichmuller C, v Bardeleben U, et al. Flupenthixol in relapse prevention in schizophrenics with comorbid alcoholism: results from an open clinical study. Eur Addict Res 2003;9(2):65-72
   PubMed Web of Science ®Google Scholar
• Rubio G, Martinez I, Ponce G, et al. Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity. Can J Psychiatry 2006;51(8):531-9
   PubMed Web of Science ®Google Scholar
• Deutsche Gesellschaft fuer Psychiatrie, Psychotherapie und Nervenheilkunde, edition. Practice guidelines in psychiatry and psychotherapy. Book 1, Practice guideline. Schizophrenia. Guideline development group. In: Gaebel W, Falkai P, Winmann S, Wobrock T. Darmstadt: Steinkopff; 2006
   Google Scholar
• Khantzian EJ. The self-medication hypothesis of substance use disorders: a reconsideration and recent applications. Harv Rev Psychiatry 1997;4(5):231-44
   PubMed Web of Science ®Google Scholar
• Siris SG, Mason SE, Bermanzohn PC, et al. Adjunctive imipramine in substance-abusing dysphoric schizophrenic patients. Psychopharmacol Bull 1993;29(1):127-33
   PubMed Web of Science ®Google Scholar
• Ziedonis D, Richardson T, Lee E, et al. Adjunctive desipramine in the treatment of cocaine abusing schizophrenics. Psychopharmacol Bull 1992;28(3):309-14
   PubMed Web of Science ®Google Scholar
• Kalyoncu A, Mirsal H, Pektas O, et al. Use of lamotrigine to augment clozapine in patients with resistant schizophrenia and comorbid alcohol dependence: a potent anti-craving effect? J Psychopharmacol 2005;19(3):301-5
   PubMed Web of Science ®Google Scholar
• Gold MS, Donabedian RK, Dillard M Jr, et al. Antipsychotic effect of opiate agonists. Lancet 1977;2(8034):398-9
   PubMed Web of Science ®Google Scholar
• Sernyak MJ, Glazer WM, Heninger GR, et al. Naltrexone augmentation of neuroleptics in schizophrenia. J Clin Psychopharmacol 1998;18(3):248-51
   PubMed Web of Science ®Google Scholar
• Petrakis IL, O'Malley S, Rounsaville B, et al. Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia. Psychopharmacology (Berl) 2004;172(3):291-7
   PubMed Web of Science ®Google Scholar
• Maxwell S, Shinderman MS. Use of naltrexone in the treatment of alcohol use disorders in patients with concomitant major mental illness. J Addict Dis 2000;19(3):61-9
   PubMed Web of Science ®Google Scholar
• Batki SL, Dimmock JA, Wade M, et al. Monitored naltrexone without counseling for alcohol abuse/dependence in schizophrenia-spectrum disorders. Am J Addict 2007;16(4):253-9
   PubMed Web of Science ®Google Scholar
• Kofoed L, Kania J, Walsh T, Atkinson RM. Outpatient treatment of patients with substance abuse and coexisting psychiatric disorders. Am J Psychiatry 1986;143(7):867-72
   PubMed Web of Science ®Google Scholar
• Mueser KT, Noordsy DL, Fox L, Wolfe R. Disulfiram treatment for alcoholism in severe mental illness. Am J Addict 2003;12(3):242-52
   PubMed Web of Science ®Google Scholar
• Ewing JA, Mueller RA, Rouse BA, Silver D. Low levels of dopamine beta-hydroxylase and psychosis. Am J Psychiatry 1977;134(8):927-8
   PubMed Web of Science ®Google Scholar
• Major LF, Lerner P, Ballenger JC, et al. Dopamine-beta-hydroxylase in the cerebrospinal fluid: relationship to disulfiram-induced psychosis. Biol Psychiatry 1979;14(2):337-44
   PubMed Web of Science ®Google Scholar
• Drake RE. Management of substance use disorder in schizophrenia patients: current guidelines. CNS Spectr 2007;12(10 Suppl 17):27-32
   PubMed Web of Science ®Google Scholar
• Dickey B, Azeni H. Persons with dual diagnoses of substance abuse and major mental illness: their excess costs of psychiatric care. Am J Public Health 1996;86(7):973-7
   PubMed Web of Science ®Google Scholar
• Owen C, Rutherford V, Jones M, et al. Noncompliance in psychiatric aftercare. Community Ment Health J 1997;33(1):25-34
   PubMed Web of Science ®Google Scholar
• Ziedonis DM, Smelson D, Rosenthal RN, et al. Improving the care of individuals with schizophrenia and substance use disorders: consensus recommendations. J Psychiatr Pract 2005;11(5):315-39
   PubMedGoogle Scholar
• Carey KB. Substance use reduction in the context of outpatient psychiatric treatment: a collaborative, motivational, harm reduction approach. Community Ment Health J 1996;32(3):291-306; discussion 7-10
   PubMed Web of Science ®Google Scholar
• Gouzoulis-Mayfrank E. Dual diagnosis of psychosis and addiction. From principles to practice. Nervenarzt 2004;75(7):642-50
   PubMed Web of Science ®Google Scholar
• McHugo GJ, Drake RE, Burton HL, Ackerson TH. A scale for assessing the stage of substance abuse treatment in persons with severe mental illness. J Nerv Ment Dis 1995;183(12):762-7
   PubMed Web of Science ®Google Scholar
• Roth RM, Brunette MF, Green AI. Treatment of substance use disorders in schizophrenia: a unifying neurobiological mechanism? Curr Psychiatry Rep 2005;7(4):283-91
   PubMedGoogle Scholar
• Dixon L, Haas G, Weiden PJ, et al. Drug abuse in schizophrenic patients: clinical correlates and reasons for use. Am J Psychiatry 1991;148(2):224-30
   PubMed Web of Science ®Google Scholar
• Gawin FH. Neuroleptic reduction of cocaine-induced paranoia but not euphoria? Psychopharmacology (Berl) 1986;90(1):142-3
   PubMed Web of Science ®Google Scholar
• Richard ML, Liskow BI, Perry PJ. Recent psychostimulant use in hospitalized schizophrenics. J Clin Psychiatry 1985;46(3):79-83
   PubMed Web of Science ®Google Scholar
• Siris SG. Pharmacological treatment of substance-abusing schizophrenic patients. Schizophr Bull 1990;16(1):111-22
   PubMed Web of Science ®Google Scholar
• Green AI. Schizophrenia and comorbid substance use disorder: effects of antipsychotics. J Clin Psychiatry 2005;66(Suppl 6):21-6
   PubMed Web of Science ®Google Scholar
• Noordsy DL, Green AI. Pharmacotherapy for schizophrenia and co-occurring substance use disorders. Curr Psychiatry Rep 2003;5(5):340-6
   PubMedGoogle Scholar
• Potvin S, Stip E, Roy JY. Clozapine, quetiapine and olanzapine among addicted schizophrenic patients: towards testable hypotheses. Int Clin Psychopharmacol 2003;18(3):121-32
   PubMed Web of Science ®Google Scholar
• Lacro JP, Dunn LB, Dolder CR, et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002;63(10):892-909
   PubMed Web of Science ®Google Scholar
• Beresford TP, Arciniegas D, Clapp L, et al. Reduction of affective lability and alcohol use following traumatic brain injury: a clinical pilot study of anti-convulsant medications. Brain Inj 2005;19(4):309-13
   PubMed Web of Science ®Google Scholar
• Chambers RA, Krystal JH, Self DW. A neurobiological basis for substance abuse comorbidity in schizophrenia. Biol Psychiatry 2001;50(2):71-83
   PubMed Web of Science ®Google Scholar
• Rosner S, Leucht S, Lehert P, Soyka M. Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes. J Psychopharmacol 2008;22(1):11-23
   PubMed Web of Science ®Google Scholar
• Ballenger JC, Post RM. Carbamazepine in alcohol withdrawal syndromes and schizophrenic psychoses. Psychopharmacol Bull 1984 (Summer);20(3):572-84
   PubMedGoogle Scholar
• Olivera AA, Kiefer MW, Manley NK. Tardive dyskinesia in psychiatric patients with substance use disorders. Am J Drug Alcohol Abuse 1990;16(1-2):57-66
   PubMed Web of Science ®Google Scholar
• Farren CK, Hameedi FA, Rosen MA, et al. Significant interaction between clozapine and cocaine in cocaine addicts. Drug Alcohol Depend 2000;59(2):153-63
   PubMed Web of Science ®Google Scholar